Why We Invested: Cadenza Bio

Cortado Ventures is thrilled to have recently invested in Cadenza Bio, an Oklahoma life sciences company developing novel therapeutic drugs to treat demyelinating, inflammatory, and neurodegenerative diseases, with a first indication in multiple sclerosis (MS). Read...

Why We Invested: Lumata Health

Lumata Health: Pioneering Next-Generation Eye Care At Cortado Ventures, we are in the venture capital business of maximizing risk-adjusted returns with high-potential, early-stage startups. We seek transformative technology solutions with as little risk as possible....

Nathaniel Harding: Year in Review and 2024 Outlook

2023 Lookback for Cortado Ventures At Cortado Ventures, we’re excited for 2024. In our company meeting this week, we strategized our position in the Midcontinent market and what it will take to source, select, and support the best and most innovative startups. Let’s...

Why We Invested: Moat Biotechnology

At Cortado Ventures, we back entrepreneurs that are inventing the future, and we are thrilled about our investment in Moat Biotechnology. Moat’s technology is based on a next-generation adenovirus platform from the Mayo Clinic. Our General Partner Mike Moradi...